AbbVie Inc. (NYSE:ABBV)
Historical Stock Chart
3 Months : From Apr 2019 to Jul 2019
By Chris Wack
AbbVie (ABBV) said Friday that its phase 3 study of its glioblastoma drug depatuxizumab mafodotin didn't meet its primary endpoint.
The biopharmaceutical company said its Intellance-1 study of depatuxizumab mafodotin in patients with newly diagnosed glioblastoma failed to achieve its overall survival objective, and demonstrated no survival benefit for patients receiving Depatux-M at an interim analysis.
Abbvie said an independent data monitoring committee recommended the study be stopped due to lack of survival benefit for patients receiving Depatux-M compared with the placebo when added to the standard regimen of radiation and temozolomide.
AbbVie said no new safety findings were observed, and enrollment in all ongoing Depatux-M studies has been halted.
The Intellance-1 trial was conducted in collaboration with the RTOG Foundation, an independent, non-profit cancer research organization.
Glioblastoma, also known as glioblastoma multiforme, is an aggressive type of cancer that can occur in the brain or spinal cord.
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires
May 17, 2019 09:16 ET (13:16 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.